Gene Therapy Translational Studies for Fragile X Syndrome

$90,000 FRAXA Research Grant for 2019 – 2021

With this $90,000 award from FRAXA Research Foundation, Drs. Ernest Pedapati, Christina Gross, and student Lindsay Beasley will pursue preclinical gene therapy approaches using AAV (adeno-associated virus) vectors for treating Fragile X syndrome at Cincinnati Children’s Hospital. Dr. Craig Erickson elaborates about this in this video.

Ernest Pedapati, MD, MS
Co-Principal Investigator

Christina Gross, PhD
Co-Principal Investigator

Lindsay Beasley
FRAXA Fellow

Craig Erickson, MD, PhD

Total Funding to the Cincinnati Children’s Hospital: $252,382

Cincinnati Children’s Hospital

By Ernest Pedapati, MD, MS and Christina Gross, PhD

With the support of FRAXA, master’s student Lindsay Beasley, under the mentorship of Ernest Pedapati, MD, MS and Christina Gross, PhD, will investigate preclinical gene therapy approaches to restoring FMRP activity. Her work is part of a larger novel clinical therapeutics program in Fragile X syndrome at Cincinnati Children’s Hospital, led by Craig Erickson, MD, seeking to develop next generation biomarkers and treatments to address the core features of the disorder.

Recent headlines in diseases such as Spinal Muscular Atrophy have demonstrated the feasibility and potential of viral mediated protein replacement in single gene disorders. The absence of FMRP in the Fragile X brain leads to many unwanted downstream effects which presents significant challenges for drug development. Thus, protein replacement of FMRP in the brain may offer a unique strategy to comprehensively restore function across multiple neural pathways.

Ms. Beasley will express a series of AAV (adeno-associated virus) vectors, each expressing FMRP, in the mouse brain to identify key design characteristics of those vectors that affect safety, efficacy, and spread of protein expression. Dr. Durgesh Tiwari in Dr. Gross’ lab will train Ms. Beasley to perform conventional primary endpoints in mice studies, including molecular, cellular, and behavioral tests. However, we will also examine the effects of protein expression on mouse EEG signals which have been found to be altered in similar fashion to humans affected by Fragile X syndrome through our collaboration in a larger National Institutes of Health U54 Fragile X Center.

Ms. Beasley will receive additional training by Carrie Jonak through Devin Binder’s lab at the University of California Riverside, to extend our current single lead mouse EEG techniques into implanting 30-channel multi-electrode grids to provide sophisticated signals similar to human dense array EEG. The discovery of a neural “signature” indicating brain activity of a successful host or treatment response is a key goal of this work.

These experiments, along with others at our institution, are laying critical groundwork for the potential adoption of these powerful technologies to one day bring into the clinic.

FRMP viral expression brain

FMRP protein (red) can be detected in neurons (green) in the brain of Fmr1 knockout mice after infection with FMRP-expressing viral vector. Fmr1 knockout mice normally have no FMRP.

Pedapati, Beasley, Gross

Ernest Pedapati, MD, MS, Lindsay Beasley and Christina Gross, PhD

Explore Current Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.

Share via
Copy link